Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM75FWO)

Drug Name

PSI-697 Drug Info

Synonyms

PSI-697; UNII-LH1XC916ME; 851546-61-7; LH1XC916ME; CHEMBL219046; 2-(4-Chlorobenzyl)-3-hydroxy-7,8,9,10-tetrahydrobenzo(H)quinoline-4-carboxylic acid; 2-(4-chlorobenzyl)-3-hydroxy-7,8,9,10-tetrahydrobenzo[h]quinoline-4-carboxylic acid; SCHEMBL43527; DIEPFYNZGUUVHD-UHFFFAOYSA-N; ZINC28603970; BDBM50201984; AKOS032945074; CS-5867; DB12211; HY-15526; LS-193902; 2-(4-chloro-benzyl)-3-hydroxy-7,8,9,10-tetrahydro-benzo[h]-quinoline-4-carboxylic acid; 2-(4-Chloro-benzyl)-3-hydroxy-7,8,9,10-tetrahydro-benzo[h]quinoline-4-carboxylic

Indication

Disease Entry	ICD 11	Status	REF
Atherosclerosis	BD40	Phase 1	[1]
Thrombosis	DB61-GB90	Phase 1	[1]

Cross-matching ID

PubChem CID: 12004316
CAS Number: CAS 851546-61-7
TTD Drug ID: DM75FWO

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Discontinued Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting P-selectin (SELP)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Crizanlizumab	DMAHOVJ	Vaso-occlusive crisis	BE2Y	Approved	[3]
GMI-1070	DMJ432G	Asthma	CA23	Phase 3	[4]
Inclacumab	DMXV94M	Sickle-cell disorder	3A51	Phase 3	[5]
CY-1503	DML906E	Hypertension	BA00-BA04	Phase 2/3	[6]
BAICALEIN	DM4C7E6	Influenza virus infection	1E30-1E32	Phase 2	[7]
SelG1	DMTQ2K0	Vaso-occlusive crisis	BE2Y	Phase 2	[8]
RPSGL-Ig	DM0BFJ5	Delayed graft function	4B24.0	Phase 2	[9]
CDP-850	DMWHQM3	Solid tumour/cancer	2A00-2F9Z	Discontinued in Phase 2	[10]
CY-1787	DMWY2NT	Allergy	4A80-4A85	Discontinued in Phase 1	[11]
PURPUROGALLIN	DM63O4F	N. A.	N. A.	Terminated	[7]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
P-selectin (SELP)	TTE5VG0	LYAM3_HUMAN	Inhibitor	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT00367692) Study Evaluating PSI-697 in Patients With Scleritis. U.S. National Institutes of Health.
2	Effect of PSI-697, a novel P-selectin inhibitor, on platelet-monocyte aggregate formation in humans. J Am Heart Assoc. 2013 Jan 28;2(1):e006007.
3	Crizanlizumab: First Approval. Drugs. 2020 Jan;80(1):79-84.
4	Deal watch: Pfizer deal for selectin inhibitor highlights potential of glycomimetic drugs. Nat Rev Drug Discov. 2011 Dec 1;10(12):890.
5	Analytical comparability demonstrated for an IgG4 molecule, inclacumab, following transfer of manufacturing responsibility from Roche to Global Blood Therapeutics. Expert Opin Biol Ther. 2022 Nov;22(11):1417-1428.
6	Adjunctive selectin blockade successfully reduces infarct size beyond thrombolysis in the electrolytic canine coronary artery model. Circulation. 1995 Aug 1;92(3):492-9.
7	Rational design of novel, potent small molecule pan-selectin antagonists. J Med Chem. 2007 Mar 22;50(6):1101-15.
8	Clinical pipeline report, company report or official report of Selexys Pharmaceuticals (2011).
9	rPSGL-1-Ig, a recombinant PSGL-1-Ig fusion protein, ameliorates LPS-induced acute lung injury in mice by inhibiting neutrophil migration. Cell Mol Biol (Noisy-le-grand). 2015 Feb 28;61(1):1-6.
10	WO patent application no. 2001,0276,21, Competitive inhibition elisa for antibody detection.
11	Administration of an antibody to E-selectin in patients with septic shock. Crit Care Med. 1996 Feb;24(2):229-33.